MASSIMI, DAVIDE

MASSIMI, DAVIDE  

Mostra records
Risultati 1 - 12 di 12 (tempo di esecuzione: 0.052 secondi).
Titolo Data di pubblicazione Autori Rivista Serie Titolo libro
Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital 2020 Barberio B.Facchin S.Mele E.Sturniolo G. C.Farinati F.Zingone F.Quagliariello A.Ghisa M.Massimi D.Casadei C.Savarino E. V. + THERAPEUTIC ADVANCES IN GASTROENTEROLOGY - -
Medical and gastroenterological education during the COVID-19 outbreak 2020 Barberio, BrigidaMassimi, DavideZingone, FabianaFarinati, FabioSavarino, Edoardo V + NATURE REVIEWS. GASTROENTEROLOGY & HEPATOLOGY - -
Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study 2020 Barberio B.Zingone F.Rovigo L.Bertani L.Ghisa M.Gubbiotti A.Massimi D.Savarino E. V. + CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY - -
REAL LIFE COMPARISON OF DIFFERENT ANTI-TNF BIOLOGIC THERAPIES FOR ULCERATIVE COLITIS TREATMENT: A RETROSPECTIVE COHORT STUDY 2020 Barberio, BrigidaZingone, FabianaMaccarone, Maria ChiaraGhisa, MatteoMassimi, DavideLorenzon, GretaSavarino, Edoardo + DIGESTIVE DISEASES - -
Fecal microbiota transplantation for norovirus infection: a clinical and microbiological success. 2020 Barberio BrigidaMassimi DavideBonfante LucianaFacchin SoniaLorenzo CalòSavarino Edoardo Vincenzo + THERAPEUTIC ADVANCES IN GASTROENTEROLOGY - -
Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis 2021 Barberio, BrigidaMassimi, DavideCazzagon, NoraZingone, FabianaSavarino, Edoardo V + GASTROENTEROLOGY - -
Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study 2021 Massimi D.Barberio B.Cingolani L.Zingone F.Savarino E. V. + THERAPEUTIC ADVANCES IN GASTROENTEROLOGY - -
Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study 2021 Zingone, FabianaLupo, Maria GiovannaMarin, RaffaellaMassimi, DavideCasadei, CesareBarberio, BrigidaFerri, NicolaSavarino, Edoardo + JOURNAL OF CLINICAL GASTROENTEROLOGY - -
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator 2021 Cingolani L.Barberio B.Zingone F.Melatti P.Gubbiotti A.Massimi D.Savarino E. V. + SCIENTIFIC REPORTS - -
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study 2021 Barberio B.Cingolani L.Canova C.Buda A.Massimi D.Savarino E. V.Zingone F. + THERAPEUTIC ADVANCES IN GASTROENTEROLOGY - -
Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation 2021 Barberio, BrigidaSavarino, Edoardo VincenzoCanova, CristinaGubbiotti, AlessandroMassimi, DavideGhisa, MatteoZingone, Fabiana + INTESTINAL RESEARCH - -
A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach 2022 Barberio B.Patuzzi I.Massimi D.Zingone F.Savarino E. V. + GUT MICROBES - -